Loading...

Discounted Cash Flow (DCF) Analysis Levered


InflaRx N.V.

InflaRx N.V. (IFRX)

Healthcare

Free Cash Flow

Year
A/P
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue ---------
Revenue (%)
Operating Cash Flow ---------
Operating Cash Flow (%)
Capital Expenditure ---------
Capital Expenditure (%)
Free Cash Flow ---------

Weighted Average Cost Of Capital

Share price $ 2.69
Diluted Shares Outstanding 28.84
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 0.05
Risk-Free Rate
Market Risk Premium
Cost of Equity -2.88
Total Debt -
Total Equity 77.59
Total Capital 77.59
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue ---------
Operating Cash Flow ---------
Capital Expenditure ---------
Free Cash Flow ---------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -2.88
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -
Equity Value -
Shares Outstanding 28.84
Equity Value Per Share -